6 Best Peptides for Depression

What to Know Before Choosing a Peptide for Depression

Depression is one of the more biologically complex conditions people bring to the peptide conversation. Research now suggests there are at least six distinct subtypes, each driven by different patterns of brain circuit dysfunction, which helps explain why no single treatment works for everyone. Standard antidepressants leave a significant portion of patients without adequate relief, and that gap is a large part of why interest in peptides has grown.

A peptide earns a place in this guide because people use it for depression, or are actively discussing using it for that purpose. That is the whole test. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Whether strong clinical trial data exists is a separate question from whether a compound belongs in the conversation, and this guide treats them separately. Each entry states the evidence honestly, and thin evidence is a reason to be candid, not a reason to leave a compound off the list.

The compounds below are numbered by how prominently each appears in research and documented real-world use, not as a recommendation of one over another. Evidence quality varies considerably across these entries, from small published human trials to animal-only data to community-reported use with no formal study behind it. Understanding where each compound sits on that spectrum is exactly what this guide is designed to help with. The choice of what to actually pursue is a personal one, and the variables that determine the right fit are better handled by a personalized plan.

One important piece of context: no peptide covered here is FDA-approved for depression. The research field is moving, but as of 2026 there are no large-scale randomized controlled trials completed for any peptide with depression as the primary endpoint. That does not make these compounds irrelevant. It makes honesty about their evidence state essential.

1. Selank: For Anxiety-Driven and Mixed-Presentation Depression

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide produced in the spleen. The structural modification extends its stability and allows it to interact with the central nervous system more effectively than its parent compound. Of all the peptides people discuss for depression, Selank has the most published human data behind it, which makes it the natural anchor for this list, though that data comes with important caveats.

Its primary mechanism involves the GABAergic system. GABA, short for gamma-aminobutyric acid, is the brain's main inhibitory signaling molecule, essentially the system that applies the brakes to overactivation. Selank appears to enhance GABA-A receptor activity and also modulates serotonin metabolism in the dorsal raphe nucleus, the brain region that serves as the main production site for serotonin. Beyond those two pathways, it reduces the breakdown of enkephalins, which are endogenous opioid peptides involved in managing stress and emotional tone.

The human evidence base consists of small clinical trials conducted primarily in Russia, where Selank has been used clinically for decades. These trials involved fewer than 60 participants and none qualify as large Phase III studies. The findings showed benefit for anxiety and mixed anxiety-depression presentations, but the trials were not powered to isolate depression specifically and have not been replicated in Western research settings. No large randomized controlled trial has been completed anywhere as of 2026.

In real-world use, Selank is most often administered as an intranasal spray. The nasal route is preferred because it allows peptides to travel via the olfactory nerve pathway, effectively bypassing the blood-brain barrier that would otherwise block most peptide compounds from reaching their central nervous system targets. Community reports describe a calming, stabilizing effect without sedation, and many users combine it with Semax for what they describe as a synergistic effect on mood and cognition. It is not FDA-approved, is sold online as a research chemical in the US, and quality control varies significantly across sources. The FDA has flagged concerns about immunogenicity and impurities from unregulated manufacturing.

2. Semax: For the Neuroplasticity Deficit in Depression

Semax is a synthetic peptide derived from a fragment of ACTH, the adrenocorticotropic hormone that plays a central role in the body's stress response. The specific fragment is ACTH(4-10), and the synthetic version is modified to be more stable and to remove the hormonal activity of the original molecule, leaving the neuroprotective and neuroplastic properties intact.

Its most discussed mechanism in the context of depression is BDNF activation. BDNF stands for brain-derived neurotrophic factor, a protein that acts as a maintenance and growth signal for neurons, supporting their survival, the formation of new connections between them, and the brain's capacity to adapt under stress. Chronic depression is associated with depleted BDNF and disrupted TrkB receptor signaling, where TrkB is the receptor that BDNF binds to in order to produce its effects. Semax appears to activate the BDNF-TrkB pathway via a signaling cascade running through the MC4R receptor, cAMP (a cellular messenger molecule), and CREB (a transcription factor that switches on genes related to neuronal growth). In plain terms, it stimulates the biological machinery that healthy neuroplasticity depends on and that depression tends to suppress. Animal models also show it raises dopamine, serotonin, and norepinephrine levels.

On the human evidence side, the picture is less direct. Semax has decades of clinical use in Russia for neurological and cognitive applications, and that history informs its current use in Western biohacking communities for mood and cognitive enhancement. However, no published randomized controlled trial has used depression as its primary endpoint. The evidence for mood effects in humans is indirect, built from cognitive-outcome studies and observational data rather than depression-specific trials.

Semax is taken intranasally, like Selank, and the two are frequently combined. It is not FDA-approved in the US, and as with Selank, product quality from research-chemical sources is not guaranteed.

3. Oxytocin: For Social Isolation and Trauma-Linked Depression

Oxytocin is an endogenous nonapeptide, a nine-amino-acid hormone produced in the hypothalamus and released from the pituitary gland. Most people know it as the bonding hormone, a name it earned from its role in childbirth, breastfeeding, and social attachment. That same social bonding function is what draws interest for a specific subset of depressive presentations, those where isolation, relational trauma, or difficulty with social connection are central features.

Its mechanism in this context involves reducing the physiological stress response during social situations, dampening fear and threat responses processed by the amygdala (the brain's alarm center), and improving the processing of social information and emotional cues. For people whose depression is tightly coupled to social withdrawal, difficulty trusting others, or trauma responses that interfere with normal social functioning, the rationale is that addressing those barriers may support broader mood improvement.

The evidence picture here is honest: oxytocin's human trial data is primarily in social anxiety and social cognition, not depression as a standalone diagnosis. The link to depression is more theoretical and indirect than clinical. Some practitioners use intranasal oxytocin off-label for emotional well-being and social functioning, but no clinical trial has demonstrated that it reduces depressive symptoms in a controlled, measurable way for a general major depressive disorder population.

FDA-approved oxytocin exists under the brand name Pitocin, but that approval covers obstetric use only, specifically labor induction and postpartum hemorrhage management. Intranasal oxytocin for psychiatric or mood applications is not FDA-approved. It is available through some compounding pharmacies and as a research-chemical product, with the nasal spray route preferred for CNS delivery.

4. DSIP: For Sleep-Disrupted Depression

DSIP, or delta sleep-inducing peptide, is a nonapeptide first identified in the 1970s through research on sleep regulation. Its name comes from its original observed effect: the ability to induce slow-wave deep sleep, specifically Stage 3 and Stage 4, when administered to experimental animals. That sleep-induction property is the primary reason it enters the depression conversation, because the relationship between disrupted sleep and depressive symptoms runs in both directions. Poor sleep worsens depression, and depression disrupts sleep architecture, creating a reinforcing cycle.

The proposed mechanism involves enhancing the restorative phases of sleep while also lowering cortisol (the primary stress hormone) and supporting parasympathetic nervous system tone, the branch of the autonomic nervous system responsible for rest and recovery. For people whose depressive symptoms are substantially driven by chronic sleep disruption, targeting that pathway specifically has a plausible rationale.

The honest assessment, however, is that DSIP is one of the more problematic compounds in this space from a reliability standpoint. Human study results are inconsistent across the available research, which appears partly due to the peptide's inherent instability. It has a very short half-life and degrades rapidly in plasma, making bioavailability variable and effects difficult to predict from one use to the next. Community use exists, primarily around bedtime for sleep optimization, but the reports are less consistent than those for Selank or Semax. No human clinical trial has established clear efficacy for depression specifically. The evidence here is experiential rather than clinical, applied to a mechanistically plausible but unproven use case.

DSIP is available as a research chemical and is used intranasally or by injection. It is not FDA-approved.

5. BPC-157: For Gut-Brain and Neurochemical Repair

BPC-157, or body protection compound-157, is a synthetic pentadecapeptide, a 15-amino-acid sequence derived from a protein found in gastric juice. It has the most extensive community use of any peptide on this list, though almost none of that use targets depression specifically. BPC-157 is primarily discussed for injury recovery, tendon and ligament repair, and gut health. It appears here because its mechanisms touch several biological systems implicated in depression, and because a meaningful subset of the biohacking community uses it for brain health and mood alongside its more established applications.

The mechanisms with potential relevance to depression include upregulation of BDNF, the same neurotrophic pathway central to Semax's proposed effects; modulation of the dopaminergic system; and influence on the gut-brain axis. The gut-brain axis is a bidirectional communication pathway in which gut health influences neurotransmitter production and inflammatory signaling in the brain. BPC-157's documented effects on gut healing give it a theoretically relevant connection to mood, even if that connection has not been studied directly in humans for depression.

No human randomized controlled trial has been published for BPC-157 with any mood-related endpoint as of 2026. The mood-relevant data comes entirely from rodent studies, which have shown interesting results but have not been translated into controlled human trials for this application. Community reports of mood-adjacent benefits exist but are anecdotal and not separable from the broader recovery and wellness effects users attribute to the compound.

BPC-157's regulatory situation in the US has been complicated. It was classified as a Category 2 bulk drug substance, effectively blocking compounding, in 2023. A February 2026 proposal may restore compounding access, though that would not constitute FDA approval. It remains available as a research chemical through online sources, carrying all the purity and sterility caveats that status involves.

6. GLP-1 Receptor Agonists: A Complicated Picture for Mood

GLP-1 receptor agonists are peptide-based compounds originally developed for type 2 diabetes and obesity management. Semaglutide and tirzepatide are the most widely known, and their use has expanded dramatically in recent years. They appear in this guide not because they are used to treat depression, but because they are widely used by people who have depression, because their mechanisms include several pathways relevant to mood, and because the community discussion of their mood effects has become too prominent and too mixed to exclude.

The biological case for potential antidepressant effects includes their influence on neurogenesis, neuroinflammation reduction, insulin sensitivity in the brain (disrupted insulin signaling is increasingly linked to cognitive and mood dysregulation), and BDNF-TrkB pathway restoration. A systematic review of three clinical trials found that one showed statistically significant antidepressant effects while the others did not, leaving the efficacy picture genuinely unclear.

What cannot be left out is the other side. Community reports and one published observational study have associated GLP-1 receptor agonist use with worsening depression in some users. Reported effects in this category include anhedonia (the loss of the ability to feel pleasure), emotional numbness, and diminished motivation. The FDA evaluated reports of suicidal thoughts and actions in GLP-1 patients and subsequently requested removal of the suicidal behavior warning from their labels based on clinical trial data, though monitoring continues and the overall picture remains complex. Users and some clinicians report that semaglutide and tirzepatide may have different mood profiles, with tirzepatide generating fewer negative mood reports, but this has not been established in controlled research.

GLP-1 receptor agonists are FDA-approved for diabetes and obesity, not depression. They are among the most widely prescribed compounds in the world, available through standard prescriptions and telehealth. Anyone using them who notices mood changes warrants a direct conversation with their prescribing physician.

How These Peptides Compare

Frequently Asked Questions

Are Any of These Peptides FDA-Approved for Depression?

No peptide is FDA-approved for the treatment of depression as of 2026. GLP-1 receptor agonists are FDA-approved for diabetes and obesity, and oxytocin has an approved obstetric formulation, but neither carries a depression indication. Selank and Semax have clinical history in Russia, where they have been used for neurological and anxiety-related conditions, but that does not constitute FDA approval. All compounds discussed here are used for mood-related purposes on an off-label or research basis.

How Is Selank Different from a Benzodiazepine?

Both work on the GABAergic system, but the mechanisms differ meaningfully. Benzodiazepines bind directly to GABA-A receptors and produce strong, rapid sedation alongside a well-established dependence risk. Selank appears to modulate GABAergic activity more indirectly, and available reports from clinical use in Russia and community use globally have not identified the dependence profile associated with benzodiazepines. That said, no large controlled trial has directly compared the two, and the absence of a documented dependence signal is not the same as a confirmed clean safety record.

Can GLP-1 Peptides Make Depression Worse?

For some users, yes. Community reports describe a subset of people experiencing worsening mood, anhedonia, or emotional blunting on GLP-1 receptor agonists, particularly semaglutide. A 2024 observational study flagged elevated rates of major depression and suicidal behavior in a GLP-1-treated group, though the FDA reviewed broader clinical trial data and subsequently removed the suicidal behavior warning from GLP-1 labels, reflecting how complex and unsettled the picture remains. Anyone using a GLP-1 agent who notices mood changes should raise it directly with their prescribing physician rather than managing it independently.

Why Is the Human Evidence So Thin Across This Whole Category?

Depression research has a well-documented translational problem: compounds that show strong effects in animal models often fail to replicate those results in human trials. Several peptide-based targets showed excellent preclinical results and then failed in the majority of human trials that followed, including corticotropin-releasing factor receptor antagonists, which were inactive in four out of five human studies despite strong animal data. Contributing factors include the biological heterogeneity of human depression, high placebo response rates in psychiatric trials, and the challenge of delivering peptides effectively across the blood-brain barrier. The thin human evidence for these compounds reflects that broader landscape rather than a unique failing of any individual peptide.

Do You Need a Prescription to Access These Peptides?

It depends on the compound. GLP-1 receptor agonists require a prescription and are available through standard medical care and telehealth platforms. Oxytocin in compounded intranasal form is available through some compounding pharmacies with a prescription. Selank, Semax, DSIP, and BPC-157 are not FDA-approved and are not available through standard prescriptions in the US; they circulate primarily as research chemicals through online suppliers, where purity and sterility are not independently verified. Some functional medicine and integrative practitioners work with compounded versions of certain peptides in jurisdictions where compounding remains legally available.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for depression in one place.